Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Man lost 54 Kgs in 6 months with MGB procedure
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
First and only PARP inhibitor to improve invasive disease-free survival in patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Subscribe To Our Newsletter & Stay Updated
